Analyst Ratings For NASDAQ:SAGE – SAGE Therapeutics (NASDAQ:SAGE)
Today, Cowen reiterated its Buy rating on NASDAQ:SAGE – SAGE Therapeutics (NASDAQ:SAGE) with a price target of $207.00.
Some recent analyst ratings include
- 6/14/2018-Cowen Reiterated Rating of Buy.
- 6/12/2018-Canaccord Genuity Reiterated Rating of Buy ➝ Buy.
- 6/6/2018-LADENBURG THALM/SH SH initiated coverage with a Buy rating.
- 2/26/2018-Morgan Stanley initiated coverage with a Overweight ➝ Overweight rating.
- 2/23/2018-Needham & Company LLC Reiterated Rating of Buy.
- 1/10/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
- On 5/8/2018 James M Frates, Director, sold 7,000 with an average share price of $154.00 per share and the total transaction amounting to $1,078,000.00.
- On 4/25/2018 Kimi Iguchi, CFO, sold 28,153 with an average share price of $142.73 per share and the total transaction amounting to $4,018,277.69.
- On 4/23/2018 Kimi Iguchi, CFO, sold 12,135 with an average share price of $144.48 per share and the total transaction amounting to $1,753,264.80.
- On 4/18/2018 Kevin P Starr, Director, sold 59,000 with an average share price of $168.85 per share and the total transaction amounting to $9,962,150.00.
- On 3/6/2018 Steven M Paul, Director, sold 58,139 with an average share price of $172.00 per share and the total transaction amounting to $9,999,908.00.
- On 1/10/2018 Stephen Kanes, Insider, sold 44,000 with an average share price of $177.18 per share and the total transaction amounting to $7,795,920.00.
- On 12/21/2017 Jeffrey M Jonas, CEO, sold 210,247 with an average share price of $157.45 per share and the total transaction amounting to $33,103,390.15.
Recent Trading Activity for NASDAQ:SAGE – SAGE Therapeutics (NASDAQ:SAGE)
Shares of NASDAQ:SAGE – SAGE Therapeutics closed the previous trading session at 164.81 down -4.71 2.78% with 302516 shares trading hands.